New Leksell Gamma Knife to benefit more patients with brain disease

Elekta introduces latest in cranial radiosurgery at 3rd ESTRO Forum
BARCELONA, April 25, 2015 – With the introduction of Elekta’s new Leksell Gamma
Knife® Icon™, the benefits of precision cranial radiosurgery are now available
for more patients with a wider variety of tumor types and sizes. This latest
generation stereotactic radiosurgery system for the brain, integrates advanced
motion management, dose delivery and imaging technologies, significantly
increasing the versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell
Gamma Knife Icon today at the 3rd ESTRO Forum in Barcelona.

“This is great news for patients,” says Niklas Savander, Elekta President and
CEO. “With the new functionality in Leksell Gamma Knife Icon, doctors will have
even greater flexibility in how radiosurgery is delivered, in addition to more
assurance about the radiation dose and how accurately it’s targeted. This new
Leksell Gamma Knife will further strengthen our leading position in radiosurgery
and hopefully address some of the more complex brain disorders from which many
people suffer.”

Icon provides this increased flexibility by allowing physicians to choose either
frame-based or frameless methods to immobilize the patient’s head, in addition
to the option to perform the treatment in a single session or multiple sessions
(fractions or hypofractionation). The system even enables clinicians to choose
the degree of precision needed for each patient’s case – ranging from
traditional radiosurgery accuracy to ultra-precise microradiosurgery.

“With Leksell Gamma Knife Icon, we expect two major changes,” says Professor
Jean Régis, a neurosurgeon and Gamma Knife program director at University
Hospital La Timone (Marseilles, France). “First, the system will increase
indications, in the sense that we will be able do more hypofractionation. The
second great benefit of Icon is the ability to do true adaptive radiosurgery
both interfraction and intrafraction. It has the capacity to detect and measure
position changes – to automatically propose dose planning adaptation – while
providing the operator with an estimate of the influence of these corrections
for validation."

Elekta developed Icon to be the preferred modality to treat almost any
intracranial target. It offers new functionality familiar to radiation
oncologists, such as cone beam CT, which should help increase the adoption of
radiosurgery. By being attractive to more clinics, more patients will have
access to the benefits of precision cranial radiosurgery.

Maurits Wolleswinkel, Executive Vice President Neuroscience at Elekta, says: “By
giving doctors greater clinical flexibility and precision, it should also give
patients greater confidence and peace of mind. This system is intended to give
physicians the ability and confidence to treat virtually any pathology found in
the brain with the highest precision and certainty, and the efficient workflows
that will allow them to do this every day in the clinic,” he says.

Leksell Gamma Knife Icon is not for sale or distribution in the US and is not CE
marked.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 10:15 CET on April 25, 2015.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.